Shweta Maniar Sells 3,782 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) Director Shweta Maniar sold 3,782 shares of RxSight stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total value of $173,518.16. Following the completion of the sale, the director now directly owns 10,902 shares of the company’s stock, valued at approximately $500,183.76. This represents a 25.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

RxSight Price Performance

NASDAQ:RXST opened at $46.40 on Friday. RxSight, Inc. has a 12 month low of $28.88 and a 12 month high of $66.54. The business’s 50-day moving average is $48.85 and its two-hundred day moving average is $52.44.

Analyst Ratings Changes

RXST has been the subject of several recent analyst reports. Wells Fargo & Company lowered their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Oppenheimer dropped their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research report on Tuesday, August 6th. Jefferies Financial Group began coverage on shares of RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Finally, Stifel Nicolaus reduced their target price on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $61.63.

Hedge Funds Weigh In On RxSight

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Brown Capital Management LLC acquired a new stake in RxSight in the third quarter valued at approximately $26,813,000. Point72 Asset Management L.P. grew its holdings in RxSight by 610.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 446,976 shares of the company’s stock valued at $22,094,000 after purchasing an additional 384,041 shares in the last quarter. Marshall Wace LLP purchased a new stake in RxSight during the 2nd quarter worth $19,512,000. Driehaus Capital Management LLC increased its stake in RxSight by 74.9% during the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock worth $42,490,000 after buying an additional 302,367 shares during the period. Finally, Baillie Gifford & Co. boosted its position in RxSight by 438.8% in the 2nd quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock valued at $21,554,000 after buying an additional 291,733 shares during the last quarter. 78.78% of the stock is owned by institutional investors and hedge funds.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.